MT3/QR2 melatonin binding site does not use melatonin as a substrate or a co-substrate

Journal of Pineal Research

Volumn 45, Issue 4, 2008, Pages 524-531

  Boutin, Jean A ^a   Marcheteau, Estelle ^a   Hennig, Philippe ^b   Moulharat, Natacha ^a   Berger, Sylvie ^a   Delagrange, Philippe ^b   Bouchet, Jean Paul ^b   Ferry, Gilles ^a  

^a INSTITUT DE RECHERCHES SERVIER   (France)

^b INSTITUT DE RECHERCHES SERVIER   (France)

Author keywords

Co substrate; Melatonin; MT3; Nuclear magnetic resonance; Quinone reductase 2; Redox; Substrate

Indexed keywords

KYNURENINE; MELATONIN; N 1 ACETYL N 2 FORMYL 5 METHOXYKYNURENINE; QUINONE REDUCTASE 2; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE (PHOSPHATE) DEHYDROGENASE (QUINONE); UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; BINDING SITE; CATALYSIS; CONTROLLED STUDY; ENZYME ACTIVE SITE; ENZYME SUBSTRATE; HORMONE BINDING; NONHUMAN; NUCLEAR MAGNETIC RESONANCE; OXIDATION REDUCTION REACTION;

BINDING SITES; HUMANS; KYNURAMINE; MELATONIN; NUCLEAR MAGNETIC RESONANCE, BIOMOLECULAR; OXIDATIVE STRESS; QUINONE REDUCTASES; REACTIVE OXYGEN SPECIES; RECEPTORS, MELATONIN;

EID: 53749107306     PISSN: 07423098     EISSN: 1600079X     Source Type: Journal    
DOI: 10.1111/j.1600-079X.2008.00631.x     Document Type: Article

References (40)

1. Boutin JA, Audinot V, Ferry G et al. Molecular tools to study melatonin pathways and actions. Trends Pharmacol Sci 2005 26 : 412 419.
2. Audinot V, Mailliet F, Lahaye-Brasseur C et al. New selective ligands of human cloned melatonin MT1 and MT2 receptors. Naunyn Schmiedebergs Arch Pharmacol 2003 367 : 553 561.
3. Mailliet F, Audinot V, Malpaux B et al. Molecular pharmacology of the ovine melatonin receptor: comparison with recombinant human MT1 and MT2 receptors. Biochem Pharmacol 2004 67 : 667 677.
4. Audinot V, Bonnaud A, Grandcolas L et al. Molecular cloning and pharmacological characterization of rat melatonin MT1 and MT2 receptors. Biochem Pharmacol 2008 75 : 2007 2015.
5. 125I]iodomelatonin binding sites in hamster brain membranes: pharmacological characteristics and regional distribution. Endocrinology 1988 122 : 1825 1833.
6. Dubocovich ML. Melatonin receptors: are there multiple subtypes? Trends Pharmacol Sci 1995 16 : 50 56.
7. Molinari EJ, North PC, Dubocovich ML. 2-[I-125]iodo-5-methoxy- carbonylamino-N-acetyltryptamine: a selective radioligand for the characterization of melatonin ML(2) binding sites. Eur J Pharmacol 1996 301 : 159 168.
8. Paul P, Lahaye C, Delagrange P et al. Characterization of 2-[I-125]iodomelatonin binding sites in Syrian hamster peripheral organs. J Pharmacol Exp Ther 1999 290 : 334 340.
9. Nosjean O, Ferro M, Cogé F et al. Identification of the melatonin binding site MT3 as the quinone reductase 2. J Biol Chem 2000 257 : 31311 31317.
10. Nosjean O, Nicolas JP, Klupsch F et al. Comparative pharmacological studies of melatonin receptors: MT1, MT2 and MT3/QR2. Tissue distribution of MT3/QR2. Biochem Pharmacol 2001 61 : 1369 1379.
11. Mailliet F, Ferry G, Vella F et al. Characterization of the melatoninergic MT3 binding site on the NRH: quinone oxidoreductase 2 enzyme. Biochem Pharmacol 2005 71 : 74 88.
12. Mailliet F, Ferry G, Vella F et al. Organs from mice deleted for NRH: quinone oxidoreductase 2 are deprived of the melatonin binding site MT3. FEBS Lett 2004 578 : 116 120.
13. Leclerc V, Delagrange P, Boutin JA et al. Synthesis of nitroindole derivatives as high affinity and selective MT3melatonin receptor ligands. J Med Chem 2002 45 : 1853 1859.
14. Boussard MF, Truche S, Rousseau-Rojas A et al. New ligands at the melatonin binding site MT(3). Eur J Med Chem 2006 41 : 306 320.
15. Farce A, Dilly S, Sabaouni A et al. Three-dimensional quantitative structure-activity relationship of MT3 melatonin binding site ligands: a comparative molecular field analysis. QSAR Comb Sci 2007 26 : 820 827.
16. Ettaoussi M., Peres B., Klupsch F et al. Design and synthesis of benzofuranic derivatives as new selective MT3 melatoninergic ligands. Bioorg Med Chem 2008 16 : 4954 4962.
17. Du H, Wang J, Zhang X et al. A novel quantitative structure-activity relationship method to predict the affinities of MT3 melatonin binding site. Eur J Med Chem 2008 in press).
18. Calamini B, Santarsiero BD, Boutin JA et al. Kinetic, thermodynamic, and X-ray structural insights into the interaction of melatonin and analogs with quinone reductase 2. Biochem J 2008 413 : 81 91.
19. Ross D. Quinone reductases multitasking in the metabolic world. Drug Metab Rev 2004 36 : 639 654.
20. Long DJ, Iskander K, Gaikwad A et al. Disruption of dihydronicotinamide riboside:quinone oxidoreductase 2 (NQO2) leads to myeloid hyperplasia of bone marrow and decreased sensitivity to menadione toxicity. J Biol Chem 2002 277 : 46131 46139.
21. Buryanovskyy L, Fu Y, Boyd M et al. Crystal structure of quinone reductase 2 in complex with resveratrol. Biochemistry 2004 43 : 11417 11426.
22. Chomarat P, Cogé F, Guénin SP et al. Cellular knock-down of quinone reductase 2: a laborious road to successful inhibition by RNA interference. Biochimie 2007 89 : 1264 1275.
23. Harada S, Fujii C, Hayashi A et al. An association between idiopathic Parkinson's disease and polymorphisms of phase II detoxification enzymes: glutathione S-transferase M1 and quinone oxidoreductase 1 and 2. Biochem Biophys Res Commun 2001 288 : 887 892.
24. Harada S, Tachikawa H, Kawanishi Y. A possible association between an insertion/deletion polymorphism of the NQO2 gene and schizophrenia. Psychiatr Genet 2003 13 : 205 209.
25. Wang W, Le WD, Pan T et al. Association of NRH:quinone oxidoreductase 2 gene promoter polymorphism with higher gene expression and increased susceptibility to Parkinson's disease. J Gerontol A Biol Sci Med Sci 2008 63 : 127 134.
26. Payton A, Miyajima F, Ollier W et al. Investigation of a functional quinine oxidoreductase (NQO2) polymorphism and cognitive decline. Neurobiol Aging 2008 in press).
27. Maldonado MD, Murillo-Cabezas R, Terron MP et al. The potential of melatonin in reducing the morbidity-mortality after cranicerebral trauma. J Pineal Res 2007 42 : 1 11.
28. Gutierrez-Cuesta J, Sureda FX, Romen M et al. Chronic administration of melatonin reduces cerebral injury bimarkers in SAM8 mice. J Pineal Res 2007 42 : 394 402.
29. Rennie K, De Butte M, Frechette M, Pappas BA. Chronic and acute melatonin effects in gerbil global ischemia forebrain ischemia: long-term neural and behavioral outcome. J Pineal Res 2008 44 : 149 156.
30. Tan DX, Lucien C, Manchester M et al. Melatonin as a naturally occurring co-substrate of quinone reductase-2, the putative MT3 melatonin membrane receptor: hypothesis and significance. J Pineal Res 2007 43 : 317 320.
31. Ferry G, Ubeaud C, Lambert PH et al. Molecular evidence that melatonin is enzymatically oxidized in a different manner than tryptophan: investigations with both indoleamine 2,3-dioxygenase and myeloperoxidase. Biochem J 2005 388 : 205 215.
32. Ferry G, Ubeaud C, Mozo J et al. New substrate analogues of human serotonin N-acetyltransferase produce in situ specific and potent inhibitors. Eur J Biochem 2004 271 : 418 428.
33. Boutin JA, Chatelain-Egger F, Vella F et al. Quinone reductase 2 substrate specificity and inhibition pharmacology. Chem Biol Interact 2005 151 : 213 228.
34. Criddle DN, Gillies S, Baumgartner-Wilson HK et al. Menadione-induced reactive oxygen species generation via redox cycling promotes apoptosis of murine pancreatic acinar cells. J Biol Chem 2006 281 : 40485 40492.
35. Kovacs J, Brodner W, Kirchlechner V et al. Measurement of urinary melatonin: a useful tool for monitoring serum melatonin after its oral administration. J Clin Endocrinol Metab 2000 85 : 666 670.
36. Ma X, Chen C, Krausz KW et al. A metabolomic perspective of melatonin metabolism in the mouse. Endocrinology 2006 149 : 1969 1879.
37. Celli CM, Tran N, Knox R et al. NRH:quinone oxidoreductase 2 (NQO2) catalyzes metabolic activation of quinones and anti-tumor drugs. Biochem Pharmacol 2006 72 : 366 376.
38. Liao S, Williams-Ashman HG. Enzymatic oxidation of some non-phosphorylated derivatives of dihydronicotinamide. Biochem Biophys Res Commun 1961 4 : 208 213.
39. Belenky P, Bogan KL, Brenner C. NAD+ metabolism in health and disease. Trends Biochem Sci 2007 32 : 12 19.
40. Revollo JR, Grimm AA, Imai S. The NAD biosynthesis pathway mediated by nicotinamide phosphoribosyltransferase regulates Sir2 activity in mammalian cells. J Biol Chem 2004 279 : 50754 50763.